News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,575 Results
Type
Article (14895)
Company Profile (299)
Press Release (266375)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79837)
Career Advice (162)
Deals (13336)
Drug Delivery (39)
Drug Development (50696)
Employer Resources (31)
FDA (5836)
Job Trends (5167)
News (145074)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21761)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6030)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4562)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43663)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (551)
Cystic fibrosis (112)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31645)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51658)
Executive appointments (622)
FDA (7583)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (505)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7345)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2665)
Medtech (2675)
Mergers & acquisitions (6615)
Metabolic disorders (726)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (330)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26650)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15473)
Phase 2 (20285)
Phase 3 (12819)
Pipeline (3240)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1447)
Recruiting (12)
Regulatory (9892)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (174)
Women's health (25)
Worklife (2)
Date
Today (6)
Last 7 days (344)
Last 30 days (1300)
Last 365 days (17833)
2026 (1651)
2025 (18100)
2024 (20547)
2023 (22417)
2022 (26822)
2021 (27805)
2020 (23358)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14351)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18251)
Australia (3110)
California (7075)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39155)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (162)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5581)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (825)
North Dakota (6)
Northern California (3474)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2807)
Tennessee (40)
Texas (904)
United States (23326)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,575 Results for "morphic therapeutic".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Morphic Medical Announces CEO Transition
August 6, 2025
·
3 min read
Press Releases
Morphic Medical Announces CE Mark for RESET® Endoscopic Device Therapy
July 8, 2025
·
4 min read
Genetown
Morphic to Participate in Jefferies Global Healthcare Conference
Morphic Therapeutic today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:30 AM ET.
May 31, 2024
·
1 min read
Business
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
Morphic Therapeutic today reported corporate highlights and financial results for the first quarter 2024.
April 25, 2024
·
9 min read
Genetown
Morphic to Participate in RBC Capital Markets Global Healthcare Conference
Morphic Therapeutic announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET.
May 9, 2024
·
1 min read
Business
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Morphic Therapeutic today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.
March 19, 2024
·
5 min read
Genetown
Morphic to Participate in March 2024 Investor Conferences
Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced its participation at investor conferences during the month of March.
March 5, 2024
·
1 min read
Business
Lilly Pays $3.2B to Buy Morphic and Deepen Immunology, Gastro Portfolio
Eli Lilly on Monday announced a $3.2 billion all-cash deal to purchase Morphic and its pipeline of oral integrin therapies in a move to expand the pharma’s presence in the autoimmune diseases space.
July 8, 2024
·
2 min read
·
Tristan Manalac
Genetown
Morphic to Present at November 2023 Investor Conferences
Morphic Therapeutic announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference.
November 10, 2023
·
1 min read
Drug Development
Morphic’s Ulcerative Colitis Pill Misses Expectations in Mid-Stage Study, Stock Falls
Despite meeting the primary endpoint and eliciting endoscopic improvements in ulcerative colitis, Morphic Therapeutic’s investigational pill underwhelmed investors with its stock plummeting.
September 25, 2023
·
2 min read
·
Tristan Manalac
1 of 28,158
Next
